Study to
test success of vision loss drug which could slash treatment costs for NHS
Nottingham
researchers are leading a study to test the effectiveness of a controversial
drug in the treatment of a common loss of vision.
If proved
successful in treating wet age-related macular degeneration (AMD), the use of
the drug Bevacizumab — commercially branded as Avastin® — could reduce the dose
and frequency of patients’ treatment, while potentially slashing the cost of
treating the disease for the NHS.
read more: